If You Invested in COGNITION THERAPEUTICS INC (CGTX)

Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. According to the company’s public disclosures, its research centers on neurodegenerative diseases where progressive cognitive and functional decline is driven by toxic protein interactions in the brain.

The company’s lead product candidate is zervimesine (CT1812), described as an investigational, oral, once-daily pill in development for central nervous system (CNS) diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). Cognition Therapeutics reports that zervimesine is being studied in multiple Phase 2 clinical trials and that it has completed Phase 2 studies in mild-to-moderate Alzheimer’s disease, dementia with Lewy bodies and geographic atrophy secondary to dry age-related macular degeneration (dry AMD. The company states that its ongoing Phase 2 START study is evaluating zervimesine in early Alzheimer’s disease.

Across its disclosures, Cognition Therapeutics explains that Alzheimer’s disease and DLB are associated with the buildup of proteins such as Aβ and ɑ‑synuclein in the brain. When these proteins bind to receptors on the surface of neurons, they can damage or destroy those neurons, leading to a progressive loss of memory, learning ability, movement and communication. The company reports that zervimesine has been shown in clinical and preclinical work to interrupt the toxic effects of Aβ and ɑ‑synuclein, and that it believes this may slow disease progression and improve the lives of people living with Alzheimer’s disease and DLB. The company also notes that zervimesine has been generally well tolerated in clinical studies to date.

Cognition Therapeutics describes its scientific approach as targeting pathways that are impaired in age-related degenerative diseases through interaction with the sigma‑2 receptor. The company states that this mechanism is functionally distinct from other approaches being used for the treatment of degenerative diseases. Zervimesine has been adopted by the USAN Council as the United States Adopted Name (USAN) for CT1812, reflecting its development status as a small-molecule drug candidate.

Clinical programs and key studies

Cognition Therapeutics has highlighted several clinical programs for zervimesine in its news releases and regulatory filings:

• SHINE Study (COG0201) – Mild-to-moderate Alzheimer’s disease: A double-blind, placebo-controlled Phase 2 study that enrolled adults with mild-to-moderate Alzheimer’s disease. The company reports that the study met its primary endpoints of safety and tolerability. Cognitive and functional outcomes were measured using tools such as ADAS‑Cog, MMSE, ADCS‑ADL and ADCS‑CGIC. According to company commentary, data from SHINE informed the design of a proposed Phase 3 registrational program in Alzheimer’s disease.
• SHIMMER Study (NCT05225415) – Dementia with Lewy bodies: An exploratory, double-blind, placebo-controlled Phase 2 trial in adults with mild-to-moderate DLB. Cognition Therapeutics reports that SHIMMER met its primary goal of confirming the safety and tolerability of zervimesine. The company also states that zervimesine-treated participants showed favorable changes versus placebo in behavioral, cognitive, functional and movement domains, measured with tools such as the Neuropsychiatric Inventory (NPI), Clinician Assessment of Fluctuation (CAF), Montreal Cognitive Assessment (MoCA), Cognitive Drug Research Battery (CDR) and the MDS‑Unified Parkinson’s Disease Rating Scale (MDS‑UPDRS) Part III.
• START Study (NCT05531656) – Early Alzheimer’s disease: A randomized, placebo-controlled Phase 2 study in individuals with mild cognitive impairment (MCI) or early Alzheimer’s disease who have elevated Aβ as measured by PET or CSF. The company describes START as its largest Phase 2 trial to date, designed to measure the efficacy and tolerability of once-daily oral zervimesine over 18 months. Cognition Therapeutics notes that cognition and executive function are assessed using validated tools including the Clinical Dementia Rating Scale Sum of Boxes (CDR‑SB) and ADAS‑Cog, and that biomarkers and safety findings are also evaluated.
• Expanded access program in DLB (COG1202): Cognition Therapeutics has disclosed an open-label expanded access program for eligible participants from the SHIMMER study and additional patients with mild-to-moderate DLB. Participants receive 100 mg of oral zervimesine daily for up to one year. The company attributes the program’s full enrollment to strong interest from patients and investigators.

In multiple communications, the company notes that its clinical programs have received substantial support from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), including grant funding for the SHINE and SHIMMER studies and an $81 million grant backing the START study. Cognition Therapeutics also reports collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium (ACTC) and academic investigators with expertise in Alzheimer’s disease and Lewy body dementia.

Regulatory interactions and development strategy

Cognition Therapeutics describes itself as a clinical-stage company and emphasizes its interactions with regulatory agencies. The company has reported an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding a registrational program for zervimesine in mild-to-moderate Alzheimer’s disease. According to the company, FDA feedback indicated that two six-month Phase 3 studies with adults randomized to receive 100 mg of oral zervimesine or placebo daily may be sufficient, with efficacy measured using the Integrated Alzheimer’s Disease Rating Scale (iADRS), a composite of cognition and function measures.

The company has also disclosed plans to seek alignment with the European Medicines Agency (EMA) on global registrational plans for Alzheimer’s disease and has requested a Type C meeting with the FDA to discuss next clinical studies in dementia with Lewy bodies, focusing on clinically meaningful endpoints. These communications suggest that Cognition Therapeutics is evaluating its strategy across both Alzheimer’s disease and DLB based on Phase 2 results.

In addition to clinical and regulatory progress, Cognition Therapeutics has used capital markets transactions to support its pipeline. The company has reported a registered direct offering of common stock to institutional investors and an at-the-market (ATM) equity program under an Open Market Sale Agreement, indicating that it may sell shares of common stock from time to time through a sales agent. It has also disclosed the termination of a prior ATM program and the establishment of a new one, outlining the potential aggregate value of shares that may be sold.

Stock listing and corporate status

Cognition Therapeutics, Inc. is incorporated in Delaware and its common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol CGTX. The company has described itself as an emerging growth company under applicable U.S. securities laws in multiple Form 8‑K filings. Nasdaq communications referenced in company filings indicate that Cognition Therapeutics has, at times, addressed listing compliance matters related to minimum bid price requirements and has subsequently reported regaining compliance.

Based on the available filings and news releases, there is no indication in these materials that Cognition Therapeutics has been delisted, deregistered, acquired, or has ceased operations. The company continues to describe itself as a clinical-stage biopharmaceutical issuer with ongoing trials and active engagement with regulators and investors.

Research focus and mechanism of action

Cognition Therapeutics’ disclosures consistently emphasize its focus on age-related degenerative disorders of the central nervous system. The company states that it is discovering and developing small molecule therapeutics that act on pathways impaired in these diseases. Specifically, it believes that zervimesine can regulate such pathways through interaction with the sigma‑2 receptor complex, which the company describes as functionally distinct from other treatment approaches for degenerative diseases.

The company’s public statements explain that in Alzheimer’s disease and DLB, abnormal accumulation of Aβ and ɑ‑synuclein proteins at neuronal receptors contributes to neuronal damage and loss. By interrupting the toxic effects of these proteins, zervimesine is intended to address underlying disease processes rather than only symptoms. The company has highlighted that zervimesine is orally administered once daily, and that in clinical studies to date it has been generally well tolerated, without references to increased risk of ARIA or the need for serial imaging in the context of its START study description.

Funding and collaborations

Cognition Therapeutics has reported significant non-dilutive funding from U.S. government agencies. The SHINE and SHIMMER studies were supported by grant awards from the National Institute on Aging of the NIH totaling approximately $30 million, and the START study is supported by an $81 million grant from the NIA. The company has also described collaborations with the Alzheimer’s Clinical Trials Consortium (ACTC), a network of academic sites specializing in Alzheimer’s disease clinical trials, and with investigators and organizations focused on Lewy body dementia.

In addition to grant funding, Cognition Therapeutics has disclosed equity financings, including a registered direct offering of common stock to institutional investors and the issuance of placement agent warrants in connection with that offering. The company has also established an at-the-market equity program with a sales agent under which it may sell shares of common stock up to a specified aggregate dollar amount, as described in its Form S‑3 registration statement and related prospectus supplement.

Position within the biopharmaceutical sector

Within the broader biopharmaceutical and biological product manufacturing sector, Cognition Therapeutics positions itself as a company focused on neurodegenerative and age-related CNS disorders, particularly Alzheimer’s disease and dementia with Lewy bodies. Its disclosures emphasize a small-molecule, oral approach targeting the sigma‑2 receptor and toxic protein interactions, supported by Phase 2 clinical data and substantial grant funding. Investors and observers interested in CGTX stock often review the company’s clinical trial progress, regulatory interactions, financing activities and collaborations to understand its development trajectory in these high-need therapeutic areas.